GlaxoSmithKline wins $235M from Teva in carve-out patent fight over heart drug
admin 22nd June 2017 Uncategorised 0GlaxoSmithKline’s heart drug Coreg has been around a good long while, but it still pumps out more revenue for the U.K. drug company to keep fighting patent battles over the drug. Teva now finds itself on the losing end of one of those fights in a carve-out patent battle.
More: GlaxoSmithKline wins 5M from Teva in carve-out patent fight over heart drug
Source: fierce